<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-739" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biochemistry, Gluconeogenesis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chourpiliadis</surname>
            <given-names>Charilaos</given-names>
          </name>
          <aff>General Hospital of Patras, Pathology Department</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mohiuddin</surname>
            <given-names>Shamim S.</given-names>
          </name>
          <aff>Imam Abdulrahman Bin Faisal University, Dammam</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charilaos Chourpiliadis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shamim Mohiuddin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-739.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Gluconeogenesis refers to a group of metabolic reactions in cytosol and mitochondria to maintain the blood glucose level constant throughout the fasting state. Reactions in the gluconeogenesis pathway are regulated locally and globally (by insulin, glucagon, and cortisol), and some of them are highly exergonic and irreversible.<xref ref-type="bibr" rid="article-739.r1">[1]</xref>&#x000a0;The balance between stimulatory and inhibitory hormones regulates the rate of gluconeogenesis. The liver and, secondarily, the kidney are the organs that supply circulating blood glucose to various tissues. Different tissues have multiple mechanisms to generate glucose during fasting, maintaining adequate energy levels for their proper function.<xref ref-type="bibr" rid="article-739.r2">[2]</xref></p>
      </sec>
      <sec id="article-739.s2" sec-type="Fundamentals">
        <title>Fundamentals</title>
        <p>Several tissues require continuous glucose supply, including the brain, erythrocytes, renal medulla, the lens and cornea, testes, and skeletal muscles during exercise. The brain uses glucose exclusively in both the fed and fasting states except for prolonged fasting, which uses ketones. Notably, the daily amount of glucose used by the brain accounts for 70% of the total glucose produced by the liver in a normal fasting person.<xref ref-type="bibr" rid="article-739.r3">[3]</xref></p>
        <p>Initially, during the first hours of fasting, hepatic glycogenolysis is the primary source of glucose. Glucose stored as glycogen can cover the energy needs roughly for one day; the amount of glucose supplied by glycogen reserves is 190 g, while the daily requirements for glucose are 160 g. After several hours of starvation, gluconeogenesis and glycogenolysis contribute equally to blood glucose. The amount of glucose supplied by glycogen decreases rapidly while the increase in the glucose fraction contributed by gluconeogenesis results in keeping&#x000a0;constant the total amount of glucose produced. Estimates are that 54% of glucose comes from gluconeogenesis after 14 hours of starvation, and this contribution rises to 64% after 22 hours and up to 84% after 42 hours.<xref ref-type="bibr" rid="article-739.r4">[4]</xref> However, when glycogen stores deplete, the body uses lactate, glycerol, glucogenic amino acids, and odd chain fatty acids as glucose sources. In prolonged fasting, kidney participation in gluconeogenesis increases and is responsible for about 40% of total gluconeogenesis.<xref ref-type="bibr" rid="article-739.r5">[5]</xref></p>
        <p>Alanine, produced in skeletal muscles by protein catabolism and subsequent transamination reactions, is shuttled out in blood and taken up by the liver. Inside hepatocytes, alanine undergoes transamination into pyruvate, used for gluconeogenesis. Glucose produced in the liver is shuttled out in circulation and taken up by muscle cells for use in ATP production (Cahill cycle). Other gluconeogenic amino acids (e.g., methionine, histidine, valine) and gluconeogenic and ketogenic (e.g., phenylalanine, isoleucine, threonine, tryptophane) become transaminated into different intermediates of the gluconeogenic pathway.<xref ref-type="bibr" rid="article-739.r6">[6]</xref><bold>&#x000a0;&#x000a0;</bold></p>
        <p>In red blood cells and other tissues (lens) that lack mitochondria and the exercising muscle tissue that favors anaerobic metabolism, glucose is converted to pyruvate and subsequently to lactate. Lactate is secreted into plasma and picked up by the liver for conversion into glucose (Cori cycle) via a redox reaction catalyzed by lactate dehydrogenase.<xref ref-type="bibr" rid="article-739.r7">[7]</xref></p>
        <p>Fatty acids are stored as triglycerides and mobilized by the hormone-sensitive lipase (HSL); glycerol from the triglyceride structure is released in blood to be taken up by the liver, phosphorylated by glycerol kinase, and oxidized into dihydroxyacetone phosphate -an intermediate of gluconeogenesis/ glycolysis pathway- by glycerol phosphate dehydrogenase. In contrast to the ketogenic even-chain fatty acids, Odd-chain fatty acids are converted into propionyl CoA during beta-oxidation. After several steps, propionyl CoA is converted into methylmalonyl CoA. Methylmalonyl CoA mutase/B12 catalyzes the conversion of the latter into succinyl-CoA. Succinyl-CoA is an intermediate of the TCA cycle that is eventually converted into oxaloacetic acid and enters the gluconeogenesis pathway. Even-chain fatty acids and purely ketogenic amino acids (leucine, lysine) converted to acetyl-CoA cannot enter gluconeogenesis because the step is catalyzed by pyruvate dehydrogenase (PDH) is irreversible.<xref ref-type="bibr" rid="article-739.r8">[8]</xref></p>
        <p>In certain conditions, such as ischemic strokes and brain tumor development, astrocytes have increased activity of gluconeogenic enzymes, and they use lactate, alanine, aspartate, and glutamate as substrates.<xref ref-type="bibr" rid="article-739.r9">[9]</xref></p>
        <p>
<bold>Regulation of Gluconeogenesis</bold>
</p>
        <p>Multiple factors contribute to the regulation of substrates, enzymes, and reactions involved in gluconeogenesis, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Glucagon regulates gluconeogenesis through<xref ref-type="bibr" rid="article-739.r10">[10]</xref>
<list list-type="bullet"><list-item><p>Changes in allosteric regulators (reduces the levels of fructose-2,6 bisphosphate)</p></list-item><list-item><p>Covalent modification of enzyme activity (phosphorylation of pyruvate kinase results in its inactivation)</p></list-item><list-item><p>Induction of enzymes gene expression (glucagon via CRE response elements increases the expression of PEPCK</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Acetyl CoA activates pyruvate carboxylase allosterically<xref ref-type="bibr" rid="article-739.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Substrate availability might increase or decrease the rate of gluconeogenesis</p>
          </list-item>
          <list-item>
            <p>AMP inhibits fructose-1,6 bisphosphatase allosterically<xref ref-type="bibr" rid="article-739.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>For gluconeogenesis to occur, the ADP/ATP ratio must be very low since gluconeogenesis is an energy-demanding process requiring high energy molecules to be spent in several steps.<xref ref-type="bibr" rid="article-739.r13">[13]</xref><xref ref-type="bibr" rid="article-739.r14">[14]</xref>&#x000a0;In between meals, during early fasting, when cells have generated sufficient ATP levels via the TCA cycle, the increased ATP levels inhibit several highly regulated TCA cycle enzymes (citrate synthase, isocitrate dehydrogenase, a-ketoglutarate dehydrogenase). Acetyl-CoA is the indicator of the cells' metabolic activity and functions as a gluconeogenesis regulator at a local level. Acetyl-CoA levels back up and allosterically activate pyruvate carboxylase. This prevents the simultaneous occurrence of gluconeogenesis and the TCA cycle in the cells.<xref ref-type="bibr" rid="article-739.r15">[15]</xref></p>
      </sec>
      <sec id="article-739.s3" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>Pyruvate generation from phosphoenolpyruvate is the last irreversible step of glycolysis. Once cells are committed to the gluconeogenesis pathway, sequential reverse reactions convert pyruvate to oxaloacetate and phosphoenolpyruvate (PEP).<xref ref-type="bibr" rid="article-739.r16">[16]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The first step involves pyruvate carboxylase (PC), a ligase that adds a carboxyl group on pyruvate to create oxaloacetate. The enzyme consumes one ATP molecule, uses biotin (vitamin B7) as a cofactor, and uses a CO2 molecule as a carbon source. Biotin is bound to a lysine residue of PC. After ATP hydrolysis, an intermediate molecule PC-biotin-CO2 is formed, which carboxylates pyruvate to produce oxaloacetate. Apart from forming an intermediate for gluconeogenesis, this reaction provides oxaloacetic acid to the TCA cycle (anaplerotic reaction).<xref ref-type="bibr" rid="article-739.r11">[11]</xref> In muscle cells, PC is used mainly for anaplerosis. The enzyme also requires magnesium. Pyruvate carboxylation happens in mitochondria; then, via malate shuttle, oxaloacetate is being shuttled into the cytosol to be phosphorylated. Malate can cross the inner mitochondrial membrane while oxaloacetic acid cannot. In the cytosol, along with the oxidation of oxaloacetic acid into malate, NAD+ gets reduced into NADH. The produced NADH is used in a subsequent step when 1,3 bisphosphoglycerate converts into glyceraldehyde-3 phosphate.<xref ref-type="bibr" rid="article-739.r17">[17]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The following exergonic reaction catalyzed by PEP carboxykinase (PEPCK), a lyase, uses GTP as a phosphate donor to phosphorylate oxaloacetate and form PEP. Glucocorticoids induce PEPCK gene expression; cortisol, after binding to its steroid receptor intracellularly, moves inside the cell nucleus. Then, the zinc finger domain in cortisol binds to the glucocorticoid response element (GRE) on DNA.<xref ref-type="bibr" rid="article-739.r18">[18]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The rest of the reactions are reversible and common with gluconeogenesis. Enolase, a lyase, cleaves carbon-oxygen bonds and catalyzes the conversion of PEP into 2-phosphoglycerate. Phosphoglycerate mutase, an isomerase, catalyzes the conversion of 2-phosphoglycerate &#x000a0;to 3-phosphoglycerate by transferring a phosphate from carbon-2 to carbon-3. Phosphoglycerate kinase using ATP as a phosphate donor and Mg+2 to stabilize with its positive charge, the phosphotransfer reaction converts 3-phosphoglycerate to 1,3- bisphosphoglycerate. Glyceraldehyde 3-phosphate dehydrogenase catalyzes the reduction of 1,3-bisphosphoglycerate to glyceraldehyde 3-phosphate. NADH is oxidized as it donates its electrons for the reaction. As described earlier, glycerol phosphate from triglyceride catabolism is converted eventually into DHAP. Triosephosphate isomerase converts DHAP into glyceraldehyde 3-phosphate. Aldolase A converts glyceraldehyde 3-phosphate into fructose-1,6 bisphosphate.<xref ref-type="bibr" rid="article-739.r19">[19]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The following irreversible step involves the conversion of fructose 1,6 bisphosphate into fructose-6 phosphate. This step is important as it is the rate-limiting step of gluconeogenesis. Fructose-1,6 bisphosphatase catalyzes the dephosphorylation of fructose-1,6 bisphosphate, requiring bivalent metal cations (Mg+2, Mn+2); this is a highly regulated step by global and local stimuli. Locally, increased ATP levels and increased citrate levels (the first intermediate of the TCA cycle) activate fructose-1,6 bisphosphatase. However, increased AMP and increased fructose-2,6 bisphosphate (F2,6BP) inactivate this enzyme. Glucagon binds to its receptor, a GPCR, and activates adenylate cyclase. The subsequent increase in cyclic AMP (cAMP) levels leads to the activation of protein kinase A (PKA). PKA phosphorylates fructose 2,6 bisphosphatase (F2,6BPase) and phosphofructokinase-2 (PFK-2). Phosphorylated PFK-2 is inactive, while F2,6BPase is active and catalyzes the dephosphorylation of fructose 2,6 bisphosphate. Dephosphorylated F-2,6BP is inactive; hence, it does not negatively affect F1,6BPase.<xref ref-type="bibr" rid="article-739.r20">[20]</xref><xref ref-type="bibr" rid="article-739.r21">[21]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The last irreversible reaction involves glucose-6 phosphatase catalyzing the hydrolysis of glucose-6 phosphate into glucose. This enzyme is expressed primarily in the liver, kidneys, and intestinal epithelium, and the reaction happens in the endoplasmic reticulum of the cells. Muscle cells do not express glucose-6 phosphatase as they produce glucose to maintain their energy needs.<xref ref-type="bibr" rid="article-739.r22">[22]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-739.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Glycogen Storage Disease Type 1 - Von Gierke Disease</bold>
</p>
        <p>Glycogen storage disease type 1 is a group of inherited complex metabolic disorders which share poor fasting tolerance.<xref ref-type="bibr" rid="article-739.r23">[23]</xref>&#x000a0;In Von Gierke disease, liver cells lack glucose-6 phosphatase, the enzyme required to release glucose from liver cells. This disease affects both glycogenolysis and gluconeogenesis since the missing enzyme is common in both pathways resulting in the accumulation of glucose-6 phosphate in liver cells. Symptoms include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hepatomegaly and kidney enlargement due to glycogen accumulation</p>
          </list-item>
          <list-item>
            <p>Severe fasting hypoglycemia since liver cells cannot release glucose in blood postprandially</p>
          </list-item>
          <list-item>
            <p>Lactic acidosis since accumulated glucose-6 phosphate blocks gluconeogenesis and consequently lactate uptake</p>
          </list-item>
          <list-item>
            <p>Hypertriglyceridemia, since increased levels of glucose-6 phosphate favor glycolysis and acetyl-CoA production, leading to increased malonyl-CoA synthesis and subsequent inhibition of carnitine acyltransferase 1 (the rate-limiting mitochondrial enzyme of fatty acid beta-oxidation)<xref ref-type="bibr" rid="article-739.r24">[24]</xref></p>
          </list-item>
        </list>
        <p>Hyperuricemia results from increased uric acid production and decreased uric acid excretion (uric acid competes with lactate for excretion via the same organic acid transporter in proximal renal tubules).<xref ref-type="bibr" rid="article-739.r25">[25]</xref><xref ref-type="bibr" rid="article-739.r24">[24]</xref>&#x000a0;Other symptoms include protruding abdomen (hepatomegaly), truncal obesity and short height,<xref ref-type="bibr" rid="article-739.r26">[26]</xref> muscle wasting, and a rounded doll&#x02019;s face.<xref ref-type="bibr" rid="article-739.r25">[25]</xref></p>
        <p>
<bold>Pyruvate Carboxylase Deficiency</bold>
</p>
        <p>Pyruvate carboxylase deficiency is due to the lack of pyruvate carboxylase or altered enzyme activity. It causes lactic acidosis, hyperammonemia, and hypoglycemia. Hyperammonemia is due to pyruvate not being converted into oxaloacetic acid. Oxaloacetic acid gets transaminated into aspartate; reducing aspartate levels results in the reduced introduction of ammonia into the urea cycle.<xref ref-type="bibr" rid="article-739.r27">[27]</xref></p>
      </sec>
      <sec id="article-739.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=739&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=739">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/739/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=739">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-739.s6">
        <fig id="article-739.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Glucogenic Amino Acids. This illustration shows&#x000a0;how the glucogenic amino acids enter the Krebs cycle. Image courtesy Dr Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gluconeogenesis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-739.s7">
        <title>References</title>
        <ref id="article-739.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Unraveling the Regulation of Hepatic Gluconeogenesis.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>802</fpage>
            <pub-id pub-id-type="pmid">30733709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>HV</given-names>
              </name>
              <name>
                <surname>Accili</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Hormonal regulation of hepatic glucose production in health and disease.</article-title>
            <source>Cell Metab</source>
            <year>2011</year>
            <month>Jul</month>
            <day>06</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-19</page-range>
            <pub-id pub-id-type="pmid">21723500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>SCHEINBERG</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>OBSERVATIONS ON CEREBRAL CARBOHYDRATE METABOLISM IN MAN.</article-title>
            <source>Ann Intern Med</source>
            <year>1965</year>
            <month>Feb</month>
            <volume>62</volume>
            <fpage>367</fpage>
            <page-range>367-71</page-range>
            <pub-id pub-id-type="pmid">14259220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chandramouli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ekberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schumann</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Kalhan</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Wahren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Landau</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Quantifying gluconeogenesis during fasting.</article-title>
            <source>Am J Physiol</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>273</volume>
            <issue>6</issue>
            <fpage>E1209</fpage>
            <page-range>E1209-15</page-range>
            <pub-id pub-id-type="pmid">9435538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerich</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Woerle</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Stumvoll</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Renal gluconeogenesis: its importance in human glucose homeostasis.</article-title>
            <source>Diabetes Care</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>382</fpage>
            <page-range>382-91</page-range>
            <pub-id pub-id-type="pmid">11213896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Felig</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The glucose-alanine cycle.</article-title>
            <source>Metabolism</source>
            <year>1973</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-207</page-range>
            <pub-id pub-id-type="pmid">4567003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Draoui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Feron</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments.</article-title>
            <source>Dis Model Mech</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>727</fpage>
            <page-range>727-32</page-range>
            <pub-id pub-id-type="pmid">22065843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrannini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Bevilacqua</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DeFronzo</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Effect of fatty acids on glucose production and utilization in man.</article-title>
            <source>J Clin Invest</source>
            <year>1983</year>
            <month>Nov</month>
            <volume>72</volume>
            <issue>5</issue>
            <fpage>1737</fpage>
            <page-range>1737-47</page-range>
            <pub-id pub-id-type="pmid">6138367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yip</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Geng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Cerebral Gluconeogenesis and Diseases.</article-title>
            <source>Front Pharmacol</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>521</fpage>
            <pub-id pub-id-type="pmid">28101056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>BB</given-names>
              </name>
            </person-group>
            <article-title>Glucagon and regulation of glucose metabolism.</article-title>
            <source>Am J Physiol Endocrinol Metab</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>284</volume>
            <issue>4</issue>
            <fpage>E671</fpage>
            <page-range>E671-8</page-range>
            <pub-id pub-id-type="pmid">12626323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adina-Zada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zeczycki</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Attwood</surname>
                <given-names>PV</given-names>
              </name>
            </person-group>
            <article-title>Regulation of the structure and activity of pyruvate carboxylase by acetyl CoA.</article-title>
            <source>Arch Biochem Biophys</source>
            <year>2012</year>
            <month>Mar</month>
            <day>15</day>
            <volume>519</volume>
            <issue>2</issue>
            <fpage>118</fpage>
            <page-range>118-30</page-range>
            <pub-id pub-id-type="pmid">22120519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Timson</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Fructose 1,6-<italic>bis</italic>phosphatase: getting the message across.</article-title>
            <source>Biosci Rep</source>
            <year>2019</year>
            <month>Mar</month>
            <day>29</day>
            <volume>39</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30804231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuezva</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Valcarce</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Medina</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The role of ATP/ADP ratio in the control of hepatic gluconeogenesis during the early neonatal period.</article-title>
            <source>Biochim Biophys Acta</source>
            <year>1983</year>
            <month>Sep</month>
            <day>13</day>
            <volume>759</volume>
            <issue>3</issue>
            <fpage>292</fpage>
            <page-range>292-5</page-range>
            <pub-id pub-id-type="pmid">6882806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leverve</surname>
                <given-names>XM</given-names>
              </name>
              <name>
                <surname>Fontaine</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Putod-Paramelle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rigoulet</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Decrease in cytosolic ATP/ADP ratio and activation of pyruvate kinase after in vitro addition of almitrine in hepatocytes isolated from fasted rats.</article-title>
            <source>Eur J Biochem</source>
            <year>1994</year>
            <month>Sep</month>
            <day>15</day>
            <volume>224</volume>
            <issue>3</issue>
            <fpage>967</fpage>
            <page-range>967-74</page-range>
            <pub-id pub-id-type="pmid">7925421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mart&#x000ed;nez-Reyes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chandel</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Mitochondrial TCA cycle metabolites control physiology and disease.</article-title>
            <source>Nat Commun</source>
            <year>2020</year>
            <month>Jan</month>
            <day>03</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <pub-id pub-id-type="pmid">31900386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lei</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Regulation of glycolysis and gluconeogenesis by acetylation of PKM and PEPCK.</article-title>
            <source>Cold Spring Harb Symp Quant Biol</source>
            <year>2011</year>
            <volume>76</volume>
            <fpage>285</fpage>
            <page-range>285-9</page-range>
            <pub-id pub-id-type="pmid">22096030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jitrapakdee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>St Maurice</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rayment</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cleland</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Attwood</surname>
                <given-names>PV</given-names>
              </name>
            </person-group>
            <article-title>Structure, mechanism and regulation of pyruvate carboxylase.</article-title>
            <source>Biochem J</source>
            <year>2008</year>
            <month>Aug</month>
            <day>01</day>
            <volume>413</volume>
            <issue>3</issue>
            <fpage>369</fpage>
            <page-range>369-87</page-range>
            <pub-id pub-id-type="pmid">18613815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stark</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guebre-Egziabher</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Feriod</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Ioja</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pongratz</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Bhanot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cline</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Shulman</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Kibbey</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>A role for mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) in the regulation of hepatic gluconeogenesis.</article-title>
            <source>J Biol Chem</source>
            <year>2014</year>
            <month>Mar</month>
            <day>14</day>
            <volume>289</volume>
            <issue>11</issue>
            <fpage>7257</fpage>
            <page-range>7257-63</page-range>
            <pub-id pub-id-type="pmid">24497630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Chacko</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Sunehag</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Haymond</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Measurements of Gluconeogenesis and Glycogenolysis: A Methodological Review.</article-title>
            <source>Diabetes</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>12</issue>
            <fpage>3996</fpage>
            <page-range>3996-4010</page-range>
            <pub-id pub-id-type="pmid">26604176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hers</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>The control of glycolysis and gluconeogenesis by protein phosphorylation.</article-title>
            <source>Philos Trans R Soc Lond B Biol Sci</source>
            <year>1983</year>
            <month>Jul</month>
            <day>05</day>
            <volume>302</volume>
            <issue>1108</issue>
            <fpage>27</fpage>
            <page-range>27-32</page-range>
            <pub-id pub-id-type="pmid">6137004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Redden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Menahem</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Characterization of human fructose-1,6-bisphosphatase in control and deficient tissues.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>1990</year>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>829</fpage>
            <page-range>829-48</page-range>
            <pub-id pub-id-type="pmid">1964188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van den Berghe</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Disorders of gluconeogenesis.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>1996</year>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>470</fpage>
            <page-range>470-7</page-range>
            <pub-id pub-id-type="pmid">8884571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Froissart</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Piraud</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boudjemline</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vianey-Saban</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Petit</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hubert-Buron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eberschweiler</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Gajdos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Labrune</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Glucose-6-phosphatase deficiency.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2011</year>
            <month>May</month>
            <day>20</day>
            <volume>6</volume>
            <fpage>27</fpage>
            <pub-id pub-id-type="pmid">21599942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kishnani</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Abdenur</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Arn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bali</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Boney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Dagli</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koeberl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Somers</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wechsler</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Wolfsdorf</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>MS</given-names>
              </name>
              <collab>American College of Medical Genetics and Genomics</collab>
            </person-group>
            <article-title>Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics.</article-title>
            <source>Genet Med</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>e1</fpage>
            <pub-id pub-id-type="pmid">25356975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arif</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giyanwani</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Azizullah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kumari</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Dietary Therapy for Von Gierke's Disease: A Case Report.</article-title>
            <source>Cureus</source>
            <year>2017</year>
            <month>Aug</month>
            <day>08</day>
            <volume>9</volume>
            <issue>8</issue>
            <fpage>e1548</fpage>
            <pub-id pub-id-type="pmid">29018645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derks</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>van Rijn</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2015</year>
            <month>May</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>537</fpage>
            <page-range>537-43</page-range>
            <pub-id pub-id-type="pmid">25633903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-739.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Griebel</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Porterfield</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brewster</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pyruvate carboxylase deficiency. Report of a case and additional evidence for the "mild" phenotype.</article-title>
            <source>Clin Pediatr (Phila)</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>40</volume>
            <issue>9</issue>
            <fpage>519</fpage>
            <page-range>519-21</page-range>
            <pub-id pub-id-type="pmid">11583052</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
